The "Defending Affordable Prescription Drug Costs Act" establishes protections for 340B covered entities and their contract pharmacies against discriminatory practices by health insurers, pharmacy benefit managers, and pharmaceutical manufacturers. The act prohibits these entities from engaging in the following actions:

1. Establishing lower reimbursement amounts for 340B drugs compared to non-340B drugs based solely on the drug's 340B status.
2. Imposing different fees, chargebacks, adjustments, or conditions on reimbursement for 340B covered entities than those applied to non-340B entities based on 340B status.
3. Denying or limiting participation in standard or preferred pharmacy networks based on 340B status.
4. Imposing inconsistent audit requirements related to inventory management systems with the federal 340B drug pricing program.
5. Requiring claims-level data or documentation identifying 340B drugs as a condition of reimbursement, unless mandated by the Centers for Medicare and Medicaid Services.
6. Requiring a 340B covered entity to reverse, resubmit, or clarify a claim after initial adjudication unless these actions are part of normal pharmacy business unrelated to 340B drug pricing.
7. Interfering with a 340B covered entity's choice to use a contract pharmacy for drug distribution or dispensing.
8. Including provisions in contracts that discriminate against 340B covered entities or restrict patient choices regarding prescription drugs.
9. Placing restrictions or additional charges on patients choosing to receive 340B drugs that differ from those applied to non-340B drugs.
10. Excluding any 340B covered entity from networks or refusing to contract with them for reasons not applicable to non-340B entities.
11. Imposing any other restrictions or practices not imposed on non-340B entities.

The act also prohibits pharmaceutical manufacturers, their agents, or affiliates from denying, restricting, or interfering with the acquisition or delivery of 340B drugs to contract pharmacies authorized to dispense these drugs on behalf of 340B covered entities. Additionally, manufacturers cannot impose additional terms or limitations not required by federal law as a condition of 340B participation.

340B covered entities are required to submit an annual report detailing their participation in the federal 340B drug pricing program, including financial data and the impact of savings on community benefits. Violations of this act will be considered violations of chapter 13.1 of title 6 regarding unfair sales practices. The act is set to take effect on October 1, 2025.